Gene
MPL
MPL is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (3), Actionable biomarkers (1), Trial mentions (284), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention MPL. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers. Not plotted: 1 with a planned future start.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 13 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 33 of 8,738 | 0.38% | not measured | |
| 2025 | 41 of 8,875 | 0.46% | not measured | |
| 2024 | 15 of 8,597 | 0.17% | not measured | |
| 2023 | 18 of 8,275 | 0.22% | 30 of 11,460 | 0.26% |
| 2022 | 18 of 8,285 | 0.22% | 34 of 13,598 | 0.25% |
| 2021 | 15 of 8,692 | 0.17% | 36 of 15,045 | 0.24% |
| 2020 | 7 of 7,640 | 0.09% | 23 of 14,459 | 0.16% |
| 2019 | 13 of 7,300 | 0.18% | 35 of 12,159 | 0.29% |
| 2018 | 10 of 6,927 | 0.14% | 35 of 11,854 | 0.30% |
| 2017 | 9 of 6,558 | 0.14% | 25 of 11,595 | 0.22% |
Showing 10 of 37 years.
Assay-provider ledger (3)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| AmpliSeq | Reagent supplier | No clinical or analytical validation recorded for this pair | 1 | September 01, 2016 |
| Ion Torrent Personal Genome Machine | Reagent supplier | No clinical or analytical validation recorded for this pair | 1 | September 01, 2016 |
| Illumina | Unclassified | Clinical validationAnalytical validation | 1 | January 22, 2016 |
Actionable biomarkers (1)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| MPL (W515F) | Jak Inhibitors | response-associated | Myelodysplastic/Myeloproliferative Neoplasm | Cancer Genome Interpreter |
Trial mentions (284)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT02823210 | Trial biospecimen (AACT) |
| NCT00000419 | Trial eligibility (AACT) |
| NCT01556945 | Trial eligibility (AACT) |
| NCT07017725 | Trial eligibility (AACT) |
| NCT00258635 | Trial eligibility (AACT) |
Showing 5 of 284 trial mentions.
Target-disease associations (535)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| Abnormal bleeding | phenotype | Variant curation (ClinVar / EVA) |
| Acute Leukemia | cancer or benign tumor | Literature (Europe PMC) |
| Adult-onset autosomal recessive sideroblastic anemia | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| Aicardi-Goutieres syndrome 6 | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| Aicardi-Goutières syndrome | genetic, familial or congenital disease | Mouse knockout (IMPC) |
Showing 5 of 535 associations.
Vendor sourcing (1,013)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The variant is not observed in the gnomAD v2.1.1 dataset. Frameshift: predicted to result in a loss or disruption of normal protein function through protein ... | View ClinVar record SCV002520954.1 |
| ARUP Laboratories (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The MPL c.1653+1del variant (rs755257605, ClinVar Variation ID 632897), also known as c.1653del, is reported in the literature as compound heterozygous varia... | View ClinVar record SCV005876210.1 |
| AUSL Romagna Rimini | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : 1. Diagnosis of one of the following Ph-negative myeloproliferative neoplasms: polycythemia vera, essential thrombocythemia, idiopathic myelofibrosis,... | View trial NCT06159816 |
| AUSL Romagna Rimini | Trial sponsor | Mentioned in trial textTrial free-text mention | MPL | View trial NCT06159816 |
| Abbisko Therapeutics Co., Ltd. (China) | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : * 1.Patient should understand, sign, and date the written voluntary informed consent form prior to any protocol-specific procedures performed. Patient sho... | View trial NCT07010497 |
Showing 5 of 1,013 sourcing records.
Trial-cited literature (361)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Hetrombopag Added to Cyclosporine as the First-Line Treatment for Patients With Non-Severe Aplastic Anemia: A Phase 2 Multicenter Trial. | American journal of hematology | 2026 | 1 |
| Avatrombopag for the treatment of children and adolescents with immune thrombocytopenia (AVA-PED-301): a multicentre, randomised, double-blind, placebo-controlled, phase 3b study. | The Lancet. Haematology | 2025 | 9 |
| Eltrombopag for Newly Diagnosed Pediatric Immune Thrombocytopenia Requiring Treatment: The PINES Randomized Clinical Trial. | JAMA | 2025 | 5 |
| Long-term follow-up of the STOPAGO study. | Blood | 2025 | 4 |
| Ianalumab plus Eltrombopag in Immune Thrombocytopenia. | The New England journal of medicine | 2025 | 3 |
Showing 5 of 361 papers.
Protein variant mentions (33)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A58V | 1 | 2015 | PMID 25741868 |
| p.E247K | 1 | 2022 | PMID 35203879 |
| p.F147L | 1 | 2022 | PMID 35203879 |
| p.G131S | 1 | 2023 | PMID 37647632 |
| p.G238C | 1 | 2015 | PMID 25741868 |
Showing 5 of 33 variants.
Literature-extracted relations (107)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| RITUXIMAB | Chemical | negative_correlate |
Thrombopoietin receptor agonists and rituximab for treatment of pediatric immune thrombocytopenia: A systematic review and meta-analysis of prospective clinical trials. | 2022 |
| Anemia, Aplastic | Disease | associate |
Hetrombopag Added to Cyclosporine as the First-Line Treatment for Patients With Non-Severe Aplastic Anemia: A Phase 2 Multicenter Trial. | 2026 |
| Purpura, Thrombocytopenic, Idiopathic | Disease | associate |
Long-term follow-up of the STOPAGO study. | 2025 |
| Thrombocytopenia | Disease | associate |
Romiplostim in chemotherapy-induced thrombocytopenia: A review of the literature. | 2024 |
| Purpura, Thrombocytopenic, Idiopathic | Disease | associate |
Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study. | 2024 |
Showing 5 of 107 relation assertions.
Organizations publishing (457)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Mass General Brigham | Hospital | 21 | 2006 to 2025 |
| Mayo Clinic | Hospital | 20 | 2009 to 2023 |
| University of Florence | Academic | 18 | 2013 to 2023 |
| Harvard Medical School | Academic | 17 | 2006 to 2025 |
| Memorial Sloan Kettering Cancer Center | Hospital | 17 | 2015 to 2024 |
Showing 5 of 457 organizations.
Where MPL appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- integumentary system disease
- measurement
- phenotype
471 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.